MD-OncoMD-OncoMD-Onco2782-32022782-6171Publishing House ABV Press3810.17650/2782-3202-2022-2-2-63-67SUPPORTING THERAPY ASPECTSАСПЕКТЫ ПОДДЕРЖИВАЮЩЕЙ ТЕРАПИИCardiotoxicity of anthracyclines and targeted anti-HER2/neu therapy in treatment of oncological patientsКардиотоксичность антрациклинов и таргетной aHTU-HER2/neu-тeрапии при лечении онкологических больныхhttps://orcid.org/0000-0002-9101-8606RusanovМ. О.РусановМ. О.
Russian Federation

Maksim O. Rusanov.

61/2 Schepkina St., Moscow 129110.

Русанов Максим Олегович.

129110 Москва, ул. Щепкина, 61/2.

max-rusanov@ya.ruhttps://orcid.org/0000-0003-3326-4961KogoniyaL. M.КогонияЛ. М.
Russian Federation

61/2 Schepkina St., Moscow 129110.

129110 Москва, ул. Щепкина, 61/2.

https://orcid.org/0000-0002-6672-4269ShikinaV. E.ШикинаВ. Е.
Russian Federation

61/2 Schepkina St., Moscow 129110.

129110 Москва, ул. Щепкина, 61/2.

M.F. Vladimirsky Moscow Region Scientific Research Clinical InstituteМосковский областной научно-исследовательский клинический институт им. М.Ф. Владимирского030620222263670206202202062022Copyright ©; 2022, ABV-PressCopyright ©; 2022, АБВ-пресс2022ABV-PressАБВ-прессhttps://mdonco.abvpress.ru/jour/about/editorialPolicieshttps://mdonco.abvpress.ru/jour/article/view/38

Adverse events affecting the cardiovascular system are one of the most serious problems in the general management of patients with oncological diseases, since they can jeopardize the success in the treatment of malignant neoplasms. Despite modern methods of treatment, some chemotherapeutic drugs, such as anthracyclines, HER2 /ErbB2 inhibitors can have a pronounced effect on the cardiovascular system. These toxic effects lead to cardiac arrhythmia, heart failure, vascular toxicity and even death. It is important for oncologists and cardiologists to understand the basic diagnostic and treatment strategies that should be used in the event of toxicity of this kind.

Неблагоприятные события, влияющие на сердечно-сосудистую систему, являются одной из самых серьезных проблем в общем ведении пациентов с онкологическими заболеваниями, поскольку могут поставить под угрозу успех в лечении злокачественных новообразований. Несмотря на современные методы лечения, некоторые химиотерапевтические препараты, такие как антрациклины, ингибиторы HER2/ErbB2, могут оказывать выраженное влияние на сердечно-сосудистую систему. Эти токсические эффекты приводят к нарушению ритма сердца, сердечной недостаточности, поражению сосудов и даже смерти. Онкологам и кардиологам важно понимать основные подходы к диагностике и лечению таких осложнений, используемые при возникновении токсичности подобного рода.

cardiotoxicityanthracyclinescardioncologyoncologyaccompanying therapyarterial hypertensionкардиотоксичностьантрациклиныкардиоонкологияонкологиясопроводительная терапияартериальная гипертензияCardinale D., Colombo A., Bacchiani G. et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;131(22):1981-8. DOI:10.1161/CIRCULATIONAHA.114.013777.Johnson D.B., Balko J.M., Compton M.L. et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375(18):1749-55. DOI: 10.1056/NEJMoa1609214.Moslehi J.J., Salem J.E., Sosman J.A. et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 2018;391(10124):933. DOI: 10.1016/S0140-6736(18)30533-6.Vitsenya M.V., Ageev F.T., Gilyarov M.Yu. et al. Practical recommendations for the correction of cardiovascular toxicity of antitumor drug therapy. Zlokachestvenniye opukholy = Malignant tumours. 2021;11(3s2-2):78-98. (In Russ.). DOI: 10.18027/2224-5057-2021-11-3s2-41.Виценя М.В., Агеев Ф.Т., Гиляров М.Ю. и др. Практические рекомендации по коррекции кардиоваскулярной токсичности противоопухолевой лекарственной терапии. Злокачественные опухоли 2021;11(3s2-2):78-98. DOI: 10.18027/2224-5057-2021-11-3s2-41.Lancellotti P., Suter T.M., Lopez-Fernandez T. et al. Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J 2019;40(22):1756-63. DOI: 10.1093/eurheartj/ehy453.Pareek N., Cevallos J., Moliner P. et al. Activity and outcomes of a cardiooncology service in the United Kingdom -a five-year experience. Eur J Heart Fail 2018;20(12):1721-31. DOI: 10.1002/ejhf.1292.Von Hoff D.D., Layard M.W., Basa P. et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91(5):710-7. DOI:10.7326/0003-4819-91-5-710.Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97(11):2869-79. DOI: 10.1002/cncr.11407.Chang H.M., Moudgil R., Scarabelli T. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 1. J Am Coll Cardiol 2017;70(20):2536-51. DOI: 10.1016/jjacc.2017.09.1096. [Correction in J Am Coll Cardiol 2018;71(5):587. DOI: 10.1016/j.jacc.2017.12.041].McGowan J.V., Chung R., Maulik A. et al. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 2017;31(1):63-75. DOI: 10.1007/s10557-016-6711-0.Curigliano G., Cardinale D., Suter T. et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 2012;23(Suppl 7):vii155-66. DOI: 10.1093/annonc/mds293.Fallah-Rad N., Walker J.R., Wassef A. et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011;57(22):2263-70. DOI: 10.1016/j.jacc.2010.11.063.Markman T.M., Ruble K., Loeb D. et al. Electrophysiological effects of anthracyclines in adult survivors of pediatric malignancy. Pediatr Blood Cancer 2017;64(11): e26556. DOI: 10.1002/pbc.26556.Markman T.M., Ruble K., Loeb D. et al. Electrophysiological effects of anthracyc-lines in adult survivors of pediatric malignancy. Pediatr Blood Cancer 2017;64(11): e26556. DOI: 10.1002/pbc.26556.van Dalen E.C., van der Pal H.J., Kremer L.C. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database Syst Rev 2016;3(3):CD005008. DOI: 10.1002/14651858.CD005008.pub4.Smith D.H., Adams J.R., Johnston S.R. et al. A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Ann Oncol 20O2;13(10):159O-7. DOI: 10.1093/annonc/mdf275.van Dalen E.C., Caron H.N., Dickinson H.O., Kremer L.C. Cardioprotective interventions for cancer patients receiving anthracyc-lines. Cochrane Database Syst Rev 2008;(2):CD003917. DOI: 10.1002/14651858.CD003917.pub3.van Dalen E.C., Caron H.N., Dickinson H.O., Kremer L.C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2008;(2):CD003917. DOI: 10.1002/14651858.CD003917.pub3.Schuchter L.M., Hensley M.L., Meropol N.J., Winer E.P. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002;20(12):2895-903. DOI: 10.1200/JCO.2002.04.178.Yancy C.W., Jessup M., Bozkurt B. et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on practice guidelines. Circulation 2013;128(16):1810-52. DOI: 10.1161/CIR.0b013e31829e8807.Bosch X., Rovira M., Sitges M. et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 2013;61(23):2355-62. DOI: 10.1016/j.jacc.2013.02.072.Seidman A., Hudis C., Pierri M.K. et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20(5):1215-21. DOI: 10.1200/JCO.2002.20.5.1215.Rosa G.M., Gigli L., Tagliasacchi M.I. et al. Update on cardiotoxicity of anti-cancer treatments. Eur J Clin Invest 2016;46(3):264-84. DOI: 10.1111/eci.12589.Majed B., Moreau T., Asselain B. et al. Overweight, obesity and breast cancer prognosis: optimal body size indicator cut-points. Breast Cancer Res Treat 2009;115(1):193-203. DOI: 10.1007/s10549-008-0065-7.Majed B., Moreau T., Senouci K. et al. Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat 2008;111(2):329-42. DOI: 10.1007/s10549-007-9785-3.Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4(8):579-91. DOI: 10.1038/nrc1408.Renehan A.G., Tyson M., Egger M. et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371(9612):569-78. DOI: 10.1016/S0140-6736(08)60269-X.Guenancia C., Lefebvre A., Cardinale D. et al. Obesity as a risk factor for anthracyc-lines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis. J Clin Oncol 2016;34(26): 3157-65. DOI: 10.1200/JCO.2016.67.4846.Mitra M.S., Donthamsetty S., White B., Mehendale H.M. High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity. Toxicol Appl Pharmacol 2008;231(3):413-22. DOI: 10.1016/j.taap.2008.05.006.Guenancia C., Hachet O., Aboutabl M. et al. Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity. Cancer Chemother Pharmacol 2016;77(4):777-85. DOI: 10.1007/s00280-016-2995-9.Kenchaiah S., Sesso H.D., Gaziano J.M. Body mass index and vigorous physical activity and the risk of heart failure among men. Circulation 2009;119(1):44-52. DOI: 10.1161/CIRCULATIONAHA.108.807289.Kenchaiah S., Chesebro J.H. The epidemiologic association between obesity and heart failure. Am Coll Cardiol Ext Learn 2017;49(8):4-6.Kabore E.G., Guenancia C., Vaz-Luis I. et al. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. PLoS Med 2019;16(12):e1002989. DOI: 10.1371/journal.pmed.1002989.